Risk factors
Inhibrx Biosciences (INBX) risk factors
Item 1A of every Inhibrx Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors80 risks10 new7 dropped17 reworded
Inhibrx Biosciences faces commercialization risks for ozekibart in chondrosarcoma without prior marketing experience.
Filed Mar 19, 2026 - FY2024 10-K risk factors77 risks
Clinical-stage biotechnology company with no product revenue, relying entirely on external financing and collaborations for drug development.
Filed Mar 17, 2025